The companies used Sutro Biopharma’s proprietary cell-free expression technology on a commercial scale to manufacture Sutro’s luvelta, an antibody-drug conjugate.
With capacity increasing from six to 12 bioreactors for mammalian cell culture, the CDMO says Hillerød is the largest end-to-end biopharma manufacturing site in Europe.
The CDMO will collaborate with Pandorum on its “liquid cornea” product, while providing an exclusive GMP suite for production of Genenta’s cell therapy.
